

October 29, 2009

Kyowa Hakko Kirin Co., Ltd.

Appendix to the Consolidated Financial Statements

Fiscal 2009 Interim

(April 1, 2009 - September 31, 2009)

	Index	Page
Consolidated	I. Financial results	
	1. Income	1
	2. Results by segment	1
	3. Other income	2
	4. Extraordinary income/losses	2
	5. R&D expenses	2
	6. Capital expenditure	3
	7. Depreciation expenses	3
	8. Key indicators	3
	II. Subsidiaries and affiliates	4
Non-Consolidated	III. Financial results	
	1. Net sales by division	5
R&D Pipeline		7

This document was made as a supplement to the Kessan Tanshin (financial report) for the interim period of the fiscal nine-month period ending December 31, 2010. This document contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.

1. Consolidated Financial Results

1. Trends in income

Millions of yen, rounded down

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009			
	April 1 to September 30 results (A)	April 1 to December 31 results	Full year results	April 1 to September 30 results (B)	Comparison with the April 1 to September 30 period of the previous year		April 1 to December 31 forecasts
					Change (B-A)	Percentage	
Net sales	247,769	362,278	460,183	194,395	(53,374)	78%	310,000
Gross Profit	109,345	159,870	200,297	89,844	(19,500)	82%	-
Selling, general and administrative expenses	80,180	117,174	154,910	69,064	(11,116)	86%	-
Operating income (prior to amortization of goodwill)	33,962	49,893	54,983	25,431	(8,530)	75%	41,977
Operating income	29,164	42,696	45,387	20,779	(8,384)	71%	35,000
Other income	3,093	3,736	5,871	3,372	278		-
Other expenses	1,899	3,166	4,846	1,950	50		-
Recurring income	30,357	43,265	46,412	22,201	(8,156)	73%	36,000
Extraordinary income	-	-	6,075	-	-		-
Extraordinary expenses	4,769	13,981	21,550	1,801	(2,968)		-
Net income before income taxes	25,588	29,284	30,937	20,400	(5,188)	80%	30,000
Corporate, local and enterprise taxes	16,948	18,355	18,934	9,423	(7,525)		-
Income from minority interests	353	445	276	165	(188)		-
Net income	8,285	10,483	11,726	10,811	2,526	130%	15,000

EPS before goodwill amortization (¥/share) 22.79 30.80 37.14 27.05 38.49

*Kyowa Hakko Kirin has changed its fiscal year-end from March 31 to December 31 and a financial report will be prepared for the irregular nine-month period resulting from this change.

2. Trends in results by segment

(1) Results by operating segment

Millions of yen, rounded down

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009			
	April 1 to September 30 results (A)	April 1 to December 31 results	Full year results	April 1 to September 30 results (B)	Comparison with the April 1 to September 30 period of the previous year		April 1 to December 31 forecasts
					Change (B-A)	Percentage	
Net sales	247,769	362,278	460,183	194,395	(53,374)	78%	310,000
Pharmaceuticals	108,719	161,337	210,448	103,968	(4,750)	96%	162,000
Bio-Chemicals	45,711	67,545	88,464	41,417	(4,293)	91%	70,000
Chemicals	57,204	77,322	89,204	32,854	(24,349)	57%	50,000
Food	20,804	32,834	42,468	-	(20,804)	-%	-
Other	36,572	54,502	68,733	28,927	(7,645)	79%	48,000
Total	269,011	393,542	499,319	207,168	(61,843)	77%	330,000
Eliminations	(21,241)	(31,264)	(39,135)	(12,772)	8,469	60%	(20,000)
Operating income	29,164	42,696	45,387	20,779	(8,384)	71%	35,000
*Before goodwill amortization	33,962	49,893	54,983	25,431	(8,530)	75%	41,977
Pharmaceuticals	19,699	29,662	34,832	21,363	1,664	108%	33,500
	24,013	36,134	43,460	25,677	1,664	107%	39,971
Bio-Chemicals	5,216	7,425	8,342	1,665	(3,551)	32%	3,300
	5,529	7,894	8,967	1,978	(3,551)	36%	3,769
Chemicals	2,960	3,532	(47)	(2,486)	(5,446)	-	(2,300)
	2,984	3,569	2	(2,462)	(5,446)	-	(2,263)
Food	565	999	1,086	-	(565)	-	-
	711	1,218	1,379	-	(711)	-	-
Other	687	1,060	1,094	170	(517)	25%	500
	687	1,060	1,094	170	(517)	25%	500
Total	29,128	42,680	45,308	20,712	(8,416)	71%	35,000
	33,926	49,877	54,904	25,363	(8,563)	75%	41,977
Eliminations	35	15	78	67	32	191%	-

*Figures representing goodwill before amortization have been italicized

The Food business segment has been excluded as of the fiscal period ending December 31, 2009. This is due to the sale of shares of the consolidated subsidiaries that operated the businesses at the end of the previous fiscal year.

(2) Overseas sales

Millions of yen, rounded down

	April 1, 2008 to March 31, 2009						April 1, 2008 to December 31, 2009	
	April 1 to September 30 results	Percentage of consolidated sales	April 1 to December 31 results	Percentage of consolidated sales	Full year results	Percentage of consolidated sales	April 1 to September 30 results	Percentage of consolidated sales
Overseas sales	59,032	23.8%	74,928	20.7%	88,770	19.3%	39,725	20.4%
America	23,635	9.5%	27,202	7.5%	31,023	6.7%	10,688	5.5%
Europe	12,792	5.2%	18,117	5.0%	22,631	4.9%	11,309	5.8%
Asia	22,290	9.0%	28,960	8.0%	34,254	7.4%	17,420	9.0%
Other regions	314	0.1%	647	0.2%	860	0.2%	306	0.2%
Total consolidated net sales	247,769	100.0%	362,278	100.0%	460,183	100.0%	194,395	100.0%

3. Trends in other income

Millions of yen, rounded down

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009
	April 1 to September 30 results	April 1 to December 31 results	Full year results	April 1 to September 30 results
Other income	3,093	3,736	5,871	3,372
Interest received	351	534	688	249
Dividend income	668	975	2,394	1,125
Foreign exchange gain	442	-	135	-
Income from equity method investments	694	995	1,211	945
Other	936	1,230	1,441	1,051
Other expenses	1,899	3,166	4,846	1,950
Interest expense	300	413	523	153
Foreign exchange loss	-	555	-	503
Loss from disposal of fixed assets	856	1,205	2,483	843
Other	742	991	1,839	449

4. Trends in extraordinary income / losses

Millions of yen, rounded down

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009
	April 1 to September 30 results	April 1 to December 31 results	Full year results	April 1 to September 30 results
Extraordinary income	-	-	6,075	-
Gain on sale of shares in affiliates	-	-	4,721	-
Gain of sale of investments in affiliates	-	-	1,354	-
Extraordinary losses	4,769	13,981	21,550	1,801
Loss from change in equity affiliates	-	-	-	1,379
Loss from revaluation of investment securities	180	5,266	6,634	421
Asset impairment losses	1,931	1,931	5,724	-
Integration-related expenses	1,895	4,084	5,514	-
Compensation payment	-	1,937	1,937	-
Extraordinary depreciation of fixed assets	762	762	762	-
Other	-	-	977	-

Loss from change in equity affiliates resulted from the change in holdings of equity in affiliates following the April 1, 2009 merger of Kirin Food-Tech with Kyowa Hakko Food Specialties (now Kirin Kyowa Foods), an affiliate accounted for by the equity me

5. Trends in R&D expenses

Billions of yen, rounded down

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009	
	April 1 to September 30 results	April 1 to December 31 results	Full year results	April 1 to September 30 results	April 1 to December 31 forecast
R&D (Consolidated)	25.9	36.9	48.3	19.7	33.0
R&D to net sales ratio (%)	10.5%	10.2%	10.5%	10.2%	10.8%
Pharmaceuticals	23.0	32.5	42.6	17.5	29.0
(R&D to net sales ratio) (%)	21.2%	20.2%	20.3%	16.9%	18.5%
Bio-Chemicals	1.8	2.7	3.6	1.6	3.0
Chemicals	0.5	0.8	1.1	0.5	0.9
Food	0.4	0.6	0.9	--	--
Other	0.0	0.0	0.0	0.0	0.0

6. Trends in capital expenditure

Billions of yen, rounded down

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009	
	April 1 to September 30 results	April 1 to December 31 results	Full year results	April 1 to September 30 results	April 1 to December 31 forecast
Capital expenditure (Consolidated)	8.5	12.9	18.4	15.3	27.3
Pharmaceuticals	3.6	5.5	9.6	9.4	17.5
Bio-Chemicals	2.0	3.8	5.3	3.3	5.6
Chemicals	2.4	2.9	4.3	2.5	4.0
Food	0.3	0.4	0.5	-	-
Other	0.0	0.0	0.1	0.0	0.0
Eliminations	(0.0)	(0.0)	(1.5)	(0.0)	-

7. Trends in depreciation expenses

Billions of yen, rounded down

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009	
	April 1 to September 30 results	April 1 to December 31 results	Full year results	April 1 to September 30 results	April 1 to December 31 forecast
Depreciation expenses (Consolidated)	9.6	14.3	18.7	8.6	14.0
Pharmaceuticals	4.6	6.6	8.3	3.8	5.9
Bio-Chemicals	2.4	3.7	5.0	2.6	4.3
Chemicals	2.0	3.0	4.2	2.1	3.5
Food	0.4	0.7	0.9	-	-
Other	0.0	0.0	0.1	0.0	0.1
Eliminations	(0.0)	(0.0)	(0.0)	(0.0)	-

8. Trends in key indicators

(1) Exchange rate

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009	
	April 1 to September 30 results	April 1 to December 31 results	Full year results	April 1 to September 30 results	April 1 to December 31 forecast
US Dollar (¥/US\$)	106	103	101	96	94
Euro (¥/Euro)	163	151	143	133	133

(2) Operating indicators (Consolidated)

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009
	April 1 to September 30 results	April 1 to December 31 results	Full year results	April 1 to September 30 results
(prior to amortization of goodwill)	22.79	30.80	37.14	27.05
Net income per share (yen)	14.43	18.26	20.43	18.91
Operating income to sales ratio (%)	11.8	11.8	9.9	10.7
Total assets (million yen)	748,454	725,893	699,041	716,199
Net assets (million yen)	551,817	544,037	543,070	547,942
Equity ratio (%)	73.1	74.3	77.0	75.9
Net assets per share (yen)	952.77	939.72	938.42	953.91
ROIC (Return on invested capital)*	8.2	12.1	14.5	6.6
Number of staff at end of term	7,868	7,856	7,256	7,443

$$* \text{ROIC (\%)} = \frac{\text{Operating income}}{(\text{Fixed assets} + \text{Working capital})} \times 100$$

Calculations for operating income are prior to amortization of goodwill and calculations for fixed assets do not include goodwill

IV. Subsidiaries and affiliates

(As of September 30, 2009)

Segment	Type	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
		Kirin Kunpeng (China) Bio- Pharmaceutical Co., Ltd.	70.0%	Manufacture and sale and of pharmaceuticals (China)
		Kyowa Medical Promotion Co., Ltd.	100.0%	Sales promotion of pharmaceuticals
		Kyowa Hakko Kirin America, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		BioWa, Inc.	100.0%	Out-licensing and promotion of anti-body technology (US)
		Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of outsourced pharmaceutical products
		Kyowa Hakko Kirin California, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)
		Hematech, Inc.	100.0%	Technology research for manufacture of therapeutic antibody (US)
		Hematech-GAC Venture, LLC	51.0%	Technology research for manufacture of therapeutic antibody (US)
		Jeil-Kirin Pharmaceutical Inc.	90.0%	Sales of pharmaceuticals (Korea)
		Kyowa Kirin Pharmaceuticals (Taiwan) Co., Ltd.	100.0%	Sales of pharmaceuticals (Taiwan)
		Kyowa Hakko Kirin (Hong Kong) Co., Ltd.	100.0%	Sales of pharmaceuticals (Hong Kong)
Kyowa Hakko Kirin (Singapore) Pte. Ltd.	100.0%	Sales of pharmaceuticals (Singapore)		
Bio-Chemicals	Consolidated subsidiary	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and health care products
		Daiichi Fine Chemical Co., Ltd.	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
		Biokyowa Inc.	100.0%	Manufacture and sale of amino acids (US)
		Shanghai Kyowa Amino Acid Co., Ltd.	70.0%	Manufacture and sale of amino acids (China)
		Kyowa Hakko U.S.A., Inc.	100.0%	Sale and import/export of fine chemicals including amino acids (US)
		Kyowa Hakko Europe GMBH	100.0%	Sale and import/export of fine chemicals including amino acids (Germany)
		Kyowa Italiana Farmaceutici S.R.L.	100.0%	Sale and import/export of fine chemicals including amino acids (Italy)
		Kyowa Hakko (H.K.) Co., Ltd.	100.0%	Sale and import/export of fine chemicals including amino acids (Hong Kong)
		Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		Kyowa Wellness Co., Ltd.	100.0%	Sale of healthcare products
		Shinwa Pharmaceutical Co., Ltd.	100.0%	Sale of herbal medicines and health foods
Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment		
Chemicals	Consolidated subsidiary	Kyowa Hakko Chemical Co., Ltd.	100.0%	Manufacture and sale of chemicals
	Affiliate accounted for by the equity method	J-PLUS Co., Ltd.	50.0%	Manufacture and sale of plasticizers
		Kurogane Kasei Co., Ltd.	40.0%	Manufacture and sale of plasticizers, fine chemicals, etc.
Other	Consolidated subsidiary	Miyako Kagaku Co., Ltd.	52.9%	Wholesale sales of pharmaceutical raw materials, chemicals, foods, etc.
		Chiyoda Kaihatsu Co., Ltd.	100.0%	Transportation, insurance, sale of food, etc.
		Kashiwagi Corporation	62.9%	Wholesale sales of chemicals, pharmaceutical raw materials, construction materials, etc.
	Affiliate accounted for by the equity method	Japan Synthetic Alcohol Co., Ltd.	33.3%	Manufacture and sale of industrial use alcohol
		Kirin Kyowa Foods Company, Limited	35.0%	Manufacture and sale of seasonings, confectionery and bread products
		Kyowa F.D. Foods Co., Ltd.	35.0%	Manufacture and sale of freeze-dried foods
		Ohland Foods Co., Ltd.	35.0%	Manufacture and sale of bakery products, etc.
		Kyowa HiFoods Co. Ltd.	35.0%	Import and sale of foods, etc.
		Aji-Nihon Co., Ltd.	16.2%	Manufacture and sale of foods and seasonings, etc.
		Zenmi Foods Inc.	17.5%	Manufacture and sale of seasonings

Changes to the scope of consolidation

Jewly consolidated: One company: Kyowa Hakko Kirin Pharma, Inc.

Eliminated: One company: Kyowa Hakko Kirin (Thailand) Co., Ltd.

III. Net sales by division (Items and main products presented on a Non-Consolidated basis)

Kyowa Hakko Kirin

Billions of yen, rounded down

Pharmaceuticals division (Non-Consolidated)	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009		
	April 1 to September 30 results (A)	April 1 to December 31 results	Full year results	April 1 to September 30 results (B)	Change (A-B)	April 1 to December 31 forecasts
Pharmaceutical division total	99.2	147.5	191.3	94.9	(4.3)	146.8
Central nervous system agents						
<i>Depakene</i>	5.3	8.3	10.7	5.7	0.4	8.8
<i>Topina</i>	0.3	0.6	0.9	0.8	0.5	1.1
Sensory organ agents						
<i>Patanol</i>	1.4	2.2	6.6	1.9	0.5	3.2
Circulatory organ agents						
<i>Coniel</i>	11.6	18.1	23.1	11.7	0.1	18.0
<i>Inovan + Pre Dopa</i>	1.8	2.9	3.7	1.7	(0.1)	2.7
<i>Coversyl</i>	2.6	4.0	5.0	2.4	(0.2)	3.6
Digestive organ agents						
<i>Nauzelin</i>	2.4	4.2	5.5	2.4	0.0	4.2
Other metabolic medicines						
<i>Nesp/Espo</i>	21.3	34.4	43.7	25.7	4.4	40.0
<i>Regpara</i>	1.9	3.3	4.6	3.4	1.5	5.0
Blood and humoral applications						
<i>Gran/Neu-up</i>	9.1	14.3	17.6	8.9	(0.2)	14.0
Anticancer agents						
<i>Farmorubicin + Adriacin</i>	3.8	5.9	7.4	3.3	(0.5)	5.1
<i>5-FU</i>	1.8	2.8	3.6	1.9	0.1	2.8
<i>Navelbine</i>	1.5	2.4	3.1	1.5	0.0	2.3
Antiallergic agents						
<i>Allelock</i>	9.6	15.6	25.0	10.9	1.3	17.0
<i>Celtect</i>	1.7	2.6	3.6	1.5	(0.2)	2.2
Exports and Technology Out-Licensing	22.8	26.3	29.1	11.7	(11.1)	14.7

Note 1: Figures until the second half of the fiscal year ending March 31, 2009 are the combined unit sales of the former Kirin Pharma and the former Kyowa Hakko Kogyo.

Note 2: Results based on settlement price on a shipment basis. Forecasts are based on

Kyowa Hakko Kirin
Billions of yen, rounded down

Bio-Chemicals division (Non-Consolidated)	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009		
	April 1 to September 30 results (A)	April 1 to December 31 results	Full year results	April 1 to September 30 (B)	Change (B-A)	April 1 to December 31 forecasts
Bio-Chemical division total	28.4	42.1	55.2	27.0	(1.4)	40.3
Pharmaceuticals / Industrial raw materials						
Amino acids	10.2	14.9	19.3	9.4	(0.8)	14.1
Nucleic acids and vitamins	2.9	4.0	5.0	2.1	(0.8)	3.0
Health care products	4.2	6.2	8.1	4.2	0.0	6.3
Agrochemicals, livestock and fisheries products	1.6	2.5	3.6	1.5	(0.1)	2.4
Alcohol	4.6	7.2	9.3	4.8	0.2	6.8

Note 1: Figures until the second half of the fiscal year ending March 31, 2009 are those of the Bio-Chemical division of Kyowa Hakko Kirin

Billions of yen, rounded down

Chemicals division (Non-Consolidated) (Kyowa Hakko Chemical Co., Ltd.)	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009		
	April 1 to September 30 results (A)	April 1 to December 31 results	Full year results	April 1 to September 30 (B)	Change (B-A)	April 1 to December 31 forecasts
Chemical division total	57.1	77.3	89.2	32.8	(24.3)	50.0
Solvents	25.5	35.0	39.7	14.5	(11.0)	22.0
Raw materials for plasticizers	19.7	25.9	29.4	9.9	(9.8)	16.5
Specialty chemicals	9.7	13.2	16.4	6.8	(2.9)	11.0

R&D PIPELINES

Kyowa Hakko Kirin (Phase II, Phase III)

October 29th 2009

Category	Code Name Product Name	Stage		Indication	Formulation	In-house or licensed	Remarks	
		Japan	Other countries					
Cancer/ Hematology	KW-0761	Phase II	Phase I in USA	Cancer (Hematologic tumor)	Injection	Developed In-house	Humanized monoclonal antibody	
	KRN321 Nesp	Filed Nov/2008		☆ Chemotherapy induced anemia	Injection	Kirin-Amgen	Long-acting erythropoiesis stimulating protein An approval has been given in Japan for anemia of CKD patients on dialysis.	
	AMG531	Phase III		Immune thrombocytopenic purpura	Injection	Kirin-Amgen	Thrombopoiesis stimulating peptibody Clinical development is being conducted by Amgen Development KK as per agreement	
	KW-2246	Phase III		Cancer pain	Sublingual tablet	Licensed from Orexo		
	KRN125	Phase II		Neutropenia	Injection	Kirin-Amgen	Long-acting G-CSF	
	AGS-003			Phase II in USA and	Renal Cell Carcinoma	Injection	Developed with Argos	Dendritic cell-based immunotherapeutics
	AGS-004			Phase II in Canada	HIV	Injection	Developed with Argos	Dendritic cell-based immunotherapeutics
Kidney	PB94 PHOSBLOCK		Filed in China Jun/2008	Hyperphosphatemia	Oral	Licensed from Chugai	Launched in Japan	
	KRN321 Nesp	Filed Dec/2008	Phase II in China	☆ Anemia (not on dialysis) ☆ Anemia (on dialysis)	Injection	Kirin-Amgen	Long-acting erythropoiesis stimulating protein An approval has been given in Japan for anemia of CKD patients on dialysis	
Immunology/ Allergy	KW-4679		Filed in China Jul/2008	Allergy	Oral	Developed In-house	Launched in Japan	
	Z-206 ASACOL	Phase III		Inflammatory bowel disease (Crohn's disease)	Oral (pH depend controlled- release formulation)	Licensed from Zeria Pharma.	Jointly developed with Zeria Pharma	
CNS	KW-6002	Phase III	Filed in USA Apr/2007	Parkinson's disease	Oral	Developed In-house		
	KW-6500	Phase II		Parkinson's disease	Injection	Licensed from Britannia Pharma		

Kyowa Hakko Kirin (Phase I)

Category	Code Name Product Name	Stage		Indication	Formulation	In-house or licensed	Remarks
		Japan	Other countries				
Cancer/ Hematology	KW-2450		Phase I	Cancer	Oral	Developed In-house	
	KRN654	Phase I / II		Essential thrombocythemia	Oral	Licensed from Shire	
	KW-2449		Phase I / II a in USA	Cancer	Oral	Developed In-house	
	KW-2478		Phase I in Europe	Cancer	Injection	Developed In-house	
	ARQ 197	Phase I		Cancer	Oral	Licensed from ArQule	
	KRN330		Phase I / II a in USA	Cancer	Injection	Developed In-house	Fully human monoclonal antibody
	BIW-8962		Phase I in USA	Cancer	Injection	Developed In-house	Humanized monoclonal antibody
Immunology/ Allergy	KRN951	Phase I		Cancer	Oral	Developed In-house	
	NU206		Phase I in Australia	Inflammatory bowel disease	Injection	Developed with ARCA biopharma (the former Nuvelo)	
	ASKP1240		Phase I in USA	Organ Transplant Rejection	Injection	Developed with Astellas	Fully human monoclonal antibody Jointly developed with Astellas Pharma Inc.
Other	KW-3357	Phase I	Phase III in Europe	Disseminated intravascular coagulation, Congenital antithrombin deficiency	Injection	Developed In-house	Recombinant antithrombin product
	KRN23		Phase I in USA	Hypophosphatemic disease such as X-linked Hypophosphatemia (XLH)	Injection	Developed In-house	Fully human monoclonal antibody

(Note)

In the Philippines, application for approval has been filed for Filgrastim (G-CSF)

In Thailand and Hong Kong, approval for Nesp (Long-acting erythropoietin stimulating protein) has been filed. In Korea and Taiwan, Nesp has been approved.

In Kor

■ Updated since July 29, 2009 (Area, Stage, Filed, Approved, Launched etc.)

☆ New indication

Kyowa Hakko Kirin (discontinued)

Category	Code Name Product Name	Stage		Indication	Formulation	In-house or licensed	Reason
		Japan	Other countries				
Cardiovascular	KW-3902	Phase I		Acute heart failure with renal impairment	Injection	Developed In-house	Discontinued based on Phase III clinical trials results conducted by Merck overseas